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INTRODUCTION 
Cancer is a major health problem and leading disease in many countries worldwide. 
Accordance to the survey lung cancer is the leading cancer type of men’s while breast 
cancer of women’s. Growth control of the tumors is a very complex multifactorial process 
and characterized with dedifferentiation and uncontrolled cellular proliferation.  
Natural steroid products and their synthetic analogs are intensively investigated in order to 
describe and exploit their anticancer capacity, thus it could be considered a basic source of 
innovative drugs. Therefore, steroidal-type structures with different function group may 
suggest starting structures for novel synthetic antiproliferative drugs. Diosgenin and many 
related steroidal alkaloids exhibit potent anticancer effects. The most intensively 
investigated estrane is an endogenous estradiol metabolite, 2-methoxyestradiol, which does 
not exhibit hormonal activity, but seems to be highly effective against a broad range of 
cancer cell lines. 
The most important estrogen, 17β-estradiol, is involved in many hormone-dependent 
proliferative disorders in humans, including cancers of gynecological origin and 
endometriosis. The suppression of estrogen exposure at the targeted tissue is therefore a 
part of the rational therapy and is nowadays successfully applied in patients using selective 
estrogen receptor modulators (SERMs) or aromatase inhibitors. An alternative approach, 
aiming at decreasing the level in active 17β-estradiol, is inhibition of 17β-hydroxysteroid 
dehydrogenase type 1 (17β-HSD1) which is responsible for the conversion of the much 
less potent estrogen estrone into 17β-estradiol. Since most of the targeted hormone-
dependent disorders share a proliferative character, it is conceivable that a direct 
antiproliferative action combined to the enzyme inhibition effect could be beneficial for the 
treatment of these diseases. 
The G1–S transition is governed by an orchestrated interaction of a set of regulating 
factors, including Rb (retinoblastoma protein), CDK2, CDK4/6, p16, p21 and p53 
determined crucial proteins. Entry into the S phase, and therefore cell proliferation, is 
inhibited as long as Rb remains unphosphorylated by a complex containing cyclin E–
CDK2 and cyclin D–CDK4/6. Phosphorylated Rb dissociates from factor E2F allowing the 
transcription of S-phase-specific gene. The principal regulator of the cyclin E–CDK2 
complex is tumor suppressor p21, which is transcriptionally activated by p53 encoded by 
the TP53 gene. The importance of this pathway is illustrated by the finding that nearly all 
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cancers have a mutation in the TP53 gene or in some components of its downstream event. 
The hypofunction of p16 protein (also referred to as CDK4 inhibitor) has been associated 
with several malignancies and its expression correlates with the chemotherapy response in 
patients with solid tumors. Therefore, inhibition of G1–S transition could be the target of 
innovative therapeutic modalities.  
AIMS 
The aim of the present study was the investigation of the antiproliferative properties of 
synthetic compounds selected on the base of the previously described theoretical 
considerations: 
 Investigation of antiproliferative action of newly synthesized estrone-16-oxime 
ethers in vitro using human adherent cancer cell lines. The most potent 
compounds were selected for a further set of experiments in order to describe the 
possible mechanism of the action.  
 A set of estradiol derived steroid aglycones and glycosteroids was additionally 
screened for their antiproliferative effects. 
 The determination of the antiproliferative capacity of a set of previously designed 
and synthesized nonsteroidal 17β-HSD1 inhibitors, in vitro. Further in vitro 
assays including cycle analysis, HOPI-double staining, BrdU incorporation assay, 
Caspase-3 activity assay, RT-PCR technique and Western blot studies are used to 
characterize the mechanism of the most potent agents. 
MATERIALS AND METHODS 
Investigated compounds 
63 investigated compounds of the estrone-16-oxime derivatives were substituted with 
different function groups at position 3 and 16 of ring A and D (Fig. 1). The most potent 16-
oxime (3a, 3e) included free phenolyc hydroxyl-function or sulfamate groups at position 
C3. Both the propionate-ester (10h) from the group of oxim-esters, containing a 3-benzyl-
protector group, and also the oxim-methylether (11a) from the group of oxim-ethers, 
containing p-methoxybenzyl-protector group, showed a significant cytostatic effect. 
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Figure 1. Chemical structures of four investigated steroidal oximes 
In case of estradiol-derived steroids compound 13 belongs to the aglycones while 
compounds 14 and 15 possessed glycosteroid structure (Fig. 2). 
 
Figure 2. Chemical structures of the estradiol derived steroid aglycones and glycosteroids 
All the included 17β-HSD1 inhibitors had an aromatic core with two phenolic substituents 
(Fig. 3). Five of the molecules contained thiophene (16-19) or thiazol (20) as central part. 
Compound 21 was a substituted para-terphenyl while agents 22-25 were 
diphenylnaphthols. 
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Figure 3. Chemical structures of the 17β-hydroxysteroid dehydrogenase type 1 inhibitors. 
Tumor cell lines and cell culture 
Human cancer cell lines HeLa (cervix adenocarcinoma), MCF7 (breast adenocarcinoma) 
and A431 (skin epidermoid carcinoma) as well as noncancerous MRC-5 human lung 
fibroblasts were maintained in minimal essential medium. A2780 cells (isolated from 
ovarian cancer) were maintained in RPMI medium. The cells were grown in a humidified 
atmosphere of 5% CO2 at 37 °C. 
MTT assay 
The effects on the viability of malignant cells were determined in vitro by using MTT 
assay. Cells were seeded onto 96-well plates and allowed to stand overnight, after which 
the medium containing the tested compound was added. 10 mM stock solutions of the 
tested compounds were prepared with dimethyl sulfoxide (DMSO). After a 72-hours 
incubation period, viability was determined by the addition of 20 µL MTT solution (5 
mg/mL). The precipitated formazan crystals were solubilized in DMSO and the absorbance 
was read at 545 nm with an ELISA reader. Two independent experiments were performed 
with five parallel wells and cisplatin, an agent clinically used in some gynecological 
malignancies, was used as positive controls. Sigmoidal dose-response curves were fitted to 
the measured points, and the IC50 values were calculated by means of GraphPad Prism 4.0. 
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Hoechst 33258 - propidium iodide double-staining and flow cytometric analysis 
HeLa cells were seeded into a 96-well plate (5000 cells/well). After incubation for 24 
hours with the test compound, Hoechst 33258 (HO) and propidium iodide (PI) were added 
to the culture medium to give final concentrations of 5 μg/mL and 2 μg/mL, respectively. 
The staining allowed the identification of live, early-apoptotic, late-apoptotic and necrotic 
cells. HO permeates all the cells and makes the nuclei appear blue. Apoptosis was revealed 
by nuclear changes such as chromatin condensation and nuclear fragmentation. The 
necrotic and the late-apoptotic cells were identified as cell with PI uptake, which indicates 
loss of membrane integrity, the cell nuclei being stained red. 
Flow cytometric analysis was performed in order to characterize the cellular DNA content 
of treated HeLa cells. After 24 and 48 hours treatment the DNA of cells 
(200,000/condition) was stained with PI. The samples were analyzed by FACStar and 
20,000 events were recorded, and the percentages of the cells in the different cell-cycle 
phases (subG1, G1, S and G2/M) were calculated by using winMDI2.9. The sub G1 
fractions were regarded as the apoptotic cell population. 
BrdU incorporation assay 
5-Bromo-2’-deoxyuridine (BrdU) incorporation into the cellular DNA was determined by 
BrdU Labeling and Detection Kit I and III on HeLa cells (5000 and 3000/well) treated with 
the test compound for 24 hours. The incorporation of BrdU in place of thymidine was 
monitored as a parameter for DNA synthesis. The cellular DNA was partially digested by 
nuclease treatment and peroxidase labeled antibody was added which bounded to BrdU or 
labeled with mouse monoclonal antibody. Finally, the peroxidase activity was determined 
colorimetrically by the addition of the substrate. In the case of Kit III the absorbance was 
measured with a microplate reader at 405 nm with a reference wavelength at 492 nm. Two 
independent experiments were performed with 4 parallel wells. Alternatively, the 
fluorescein-conjugated anti-mouse antibody was added and the wells were examined by 
fluorescent microscopy with the use of an appropriate optic block (ex: 465-495 nm, em: 
515-555 nm, dichromatic mirror: 505 nm, Kit I). At least 400 cells were counted from four 
parallel wells for the expression of the BrdU-positive cells. 
6 
 
Caspase-3 assay 
The activity of caspase-3 from treated cells was determined by means of a commercially 
available colorimetric kit. Briefly, HeLa cells were exposed to the test item for 48 hours 
and than scraped, counted and resuspended in lysis buffer. The caspase-3 activity was 
measured by the addition of substrate (Ac-DEVD-pNA) and the amount of product (pNA) 
was measured at 405 nm after incubation for 17 hours. Results on treated cells are given as 
fold-increase by direct comparison with the untreated control results.  
Reverse transcriptase-PCR studies 
The effects of the tested compounds on the mRNA expression pattern of retinoblastoma 
protein (Rb), cyclin-dependent kinase 2 (CDK2), cyclin-dependent kinase 4 (CDK4), 
cyclin-dependent kinase 6 (CDK6), p16, p21, p27 and p53 regulator factors were 
determined by RT-PCR in HeLa cells. After a 24 hours incubation period, total RNA was 
isolated from the cells (5x10
5
) using TRIzol Reagent and cDNA was prepared in the 
presence of RT. Human glyceraldehydes-3-phosphate dehydrogenase (hGAPDH) primers 
were used as internal control in all samples. The sequences of the oligonucleotide primers 
for Rb, CDK2, CDK4/6, p16, p21, p27 and p53 were the same as previously reported. 
Western blotting studies 
HeLa cells were treated with investigated compounds and whole-cell extracts were 
prepared by lysis buffer. 50 g of protein per well was subjected to electrophoresis on 4-
12% NuPAGE Bis-Tris Gel in XCell SureLock Mini-Cell Units. Proteins were transferred 
from gels to nitrocellulose membranes, using the iBlot Gel Transfer System. Antibody 
binding was detected with the WesternBreeze Chromogenic Western blot immunodetection 
kit. The blots were incubated on a shaker with Rb, phosphorylated Rb (pRb) and -actin 
polyclonal antibody 1:200 in the blocking buffer.  
RESULTS 
MTT assay 
All of four estrone-16-oximes (3a, 3e, 10h and 11a) affected the proliferation of HeLa 
cells comparably to the reference agent cisplatin, while MCF7, A413 and A2780 cells were 
less sensitive. The viability of noncancerous fibroblast cell line MRC-5 was affected only 
by 11a, with a higher calculated IC50 value than that of cisplatin. Agents with an 
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unsubstituted oxime function (3a and 3e) could be regarded as selective for HeLa cells, 
with some modest action against ovarian cancer (A2780) cell line, while 10h and 11a 
displayed a broader spectrum of activities (Table 1). 
Modified estrane-based steroid aglycone and glycosteroids (13, 14 and 15) exerted 
moderate antiproliferative effect against three cancer cell lines HeLa, MCF7, A2780 and 
A431. 
Compounds 16-22 exhibited antiproliferative activities comparable to that of the reference 
agent cisplatin on the HeLa cells, while the MCF7 and A2780 cells were generally less 
sensitive. None of compounds 16-22 exerted appreciable antiproliferative action against 
the noncancerous MRC-5 cells up to 30 µM. Compound 21 proved to be the most potent 
antiproliferative agent, exhibiting a lower IC50 than that of the reference compound 
cisplatin. Test substances with a hydroxyphenylnaphthalene structure (compounds 23-25) 
exhibited substantially weaker action against the cell lines used. 
Table 1. Calculated IC50 values of the tested steroids (3a-11a, 13-15) 
and 17β-HSD1 inhibitors (16-25). 
Compounds IC50 values (μM) 
HeLa cells MCF7 cells A431 cells A2780 cells MRC-5 cells 
3a 4.41 - - 18.28 - 
3e 4.04 - - 11.96 - 
10h 3.52 4.13 - 4.61 - 
11a 5.63 - 13.25 12.62 6.94 
13 15.68 19.91 15.20 10.45 - 
14 10.82 12.40 10.39 - - 
15 - 27.45 - 19.88 - 
16 5.29 25.23 - - - 
17 6.84 13.88 - - - 
18 3.81 16.11 - - - 
19 14.53 - - - - 
20 5.66 - - - - 
21 1.41 - - - - 
22 5.30 25.51 - 9.71 - 
23 - - - 25.87 n.d 
24 - - - - n.d 
25 - - - - n.d 
Cisplatin 5.66 7.99 8.81 0.86 4.13 
       -: Mean value above 30 μM; n.d: not determined 
Morphological studies and cell cycle distribution 
The presence of apoptosis or necrosis was determined according to the cell morphology 
and membrane integrity. Concentration-dependent increases in nuclear condensation and 
fragmentation and in membrane permeability were generally observed by HOPI staining. 
The most markedly perturbed membrane integrity was seen in the case of 3e, while 
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treatment with 10h resulted in pronounced nuclear condensation with poor staining, even at 
30 µM, indicating apoptotic cell death. After 24 hours unsubstituted oximes (3a and 3e) 
caused a pronounced decrease in the synthetic (S) phase of cell cycle and at the highest 
concentration applied (30 µM), an increase in the subdiploid (subG1) population. After a 
longer incubation (48 hours), 3a and 3e resulted in a concentration-dependent increase in 
the subG1 cells, but the S population was reduced (Fig. 4). At 17β-HSD 1 inhibitors the 
morphological evidence demonstrated that compound 18 was the most potent apoptosis 
inducer while compound 20 resulted in the most pronounced deterioration in membrane 
integrity, as evidenced by intensive staining with PI. After 24 hours, there was no essential 
change in the number of apoptotic cells. All the tested compounds decreased the 
population of the synthetic phase, resulting in an increase either of the G1 phase 
(compounds 16-18 and 20) or the G2/M population (compounds 18, 20 and 22). After 
treatment for 48 hours, an unequivocal cumulation of hypodiploid (subG1) populations 
was detected for all items (Fig. 5). 
 
Figure 4. Effects of 3a, 3e, 10h and 11a on cell cycle distribution after incubation for 24 (panel A) 
or 48 hours (panel B). *, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001, respectively.  
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BrdU incorporation assay 
The incorporation of BrdU into the DNA was substantially inhibited by all of the selected 
agents. Compound 3e was the most potent in inhibiting BrdU incorporation and, similarly 
to 3a, exhibited a clear concentration dependence; their actions were comparable to that of 
cisplatin. In case of 17β-HSD1 inhibitors 21 was the most potent in this regard, exerting 
more than 50% inhibition even at 3 μM (Fig. 6). 
Figure 5. Effects of 
compounds 16–18 
and 20–22 on HeLa 
cell cycle distribution 
after incubation for 
24 (left panels) and 
48 (right panels) 
hours. *, ** and *** 
indicate p < 0.05, p < 
0.01 and p < 0.001, 
respectively.  
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Figure 6. A. and .B. Incorporation of BrdU into HeLa cells after incubation for 24 hours.  
*, ** and *** indicate p<0.05, p<0.01 and p<0.001 as compared with the control cells, respectively. 
Caspase-3 activity assay 
On the basis of the cell cycle results, compounds 3a, 3e, 20 and 21 were selected for 
additional experiments in order to determine their effects on the activity of caspase-3. All 
of these agents induced a substantial increase in the activity of this apoptosis-executing 
enzyme (Fig. 7).  
 
Figure 7. Induction of caspase-3 activity after incubation with compounds 3a, 3e (A) and with 
20, 21 (B) for 48 hours. The activity of untreated cells was taken as one unit.  
*** indicates p < 0.001 as compared with the control cells. 
RT-PCR 
The expressions of cell cycle-regulating factors (CDK2, CDK4/6, p16, p21, p53 and Rb) 
that play key roles in the orchestration of the G1–S transition were additionally determined 
by means of a semiquantitative RT-PCR technique. The expression of tumor suppressor 
gene p16 was substantially and statistically significantly increased at the mRNA level 
under all tested conditions (3a and 3e). Treatment with these selected agents resulted in a 
concentration-dependent repression of CDK4 and Rb, but not of CDK6. Tumor suppressor 
gene p53 and p21 was substantially and statistically significantly increased at an mRNA 
level under all the tested conditions (16, 17 and 21). Treatment with the selected agents 
A. B. 
A. B. 
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resulted in the concentration-dependent repression of CDK2 and Rb at the level of mRNA 
expression (Fig. 8).  
Figure 8. (A.) Expression of Rb, CDK4, CDK6 and p16 at the mRNA level after incubation with compounds 
3a, and 3e for 24 hours. (B.) Expression of p53, p21, CDK2 and Rb mRNA after incubation for 24 hours with 
compounds 16, 17 and 21. *, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001, respectively. 
Western blot analysis 
Western blot analysis reduced the expression of Rb and postsynthetically phosphorylated 
Rb at a protein level. The relative expression of pRb, expressed as the density ratio 
Rb/pRb, was concentration-dependently decreased by 3a and 3e. This ratio in the control 
cells was 1.53, which was decreased to 0.59 and 0.46 by 3a, and to 1.06 and 0.80 by 3e, in 
concentrations of 3 and 10 µM, respectively. All of tested 17β-HSD1 inhibitors 
(compounds 16, 17 and 21) reduced the level of expression of phosphorylated Rb protein 
compared to the control HeLa cells. Compound 21 exerted the highest decrease in protein 
level in both 3 and 10 µM concentrations (Fig. 9).  
           
Figure 9. (A.) Expression of Rb and phosphorylated Rb at the protein level after incubation  
with compounds 3a and 3e for 24 hours. (B.) Expression of phosphorylated Rb protein level  
after 24 hours treatment with compounds 16, 17 and 21. 
A. 
B. A. 
B. 
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DISCUSSION 
The oxime function has a widely accepted role in the design and synthesis of innovative 
anticancer drugs, including molecules with a steroidal skeleton. A set of novel estrone-16-
oximes exerted antiproliferative property against human adherent cancer cells and the most 
effective agents were selected for additional experiments in order to elucidate the possible 
mechanism of the detected action. These members of the group induced cell cycle 
disturbances and programmed cell death as evidenced by flow cytometric analysis and 
increased the caspase-3 activity. Based on the decreased BrdU incorporation disturbed 
DNA synthesis can be suggested which could be responsible for the improperly 
orchestrated machinery of cell cycle regulating factors.   
Similary, 17β-HSD1 inhibitors with natural polyphenol-related structures inhibited cancer 
cell growth, induced cell cycle disturbances and apoptosis. Our results indicate that the 
presented highly selective anticancer properties of the tested agents are not directly related 
to their originally described enzyme inhibitory action. 
In conclusion, our current results provide the first evidence that substituted estrone oximes 
may selectively suppress cancer cell proliferation by promoting apoptotic cell death and 
modulate the cell cycle progression. Although relatively high concentrations are needed to 
exert substantial activity, their cancer selectivity seems to be more beneficial than that of 
the reference agent cisplatin. Accordingly, the estrone oxime skeleton is suggested as an 
appropriate scaffold for the design and development of novel antiproliferative agents. 
In summary, 17β-HSD1 blockade may be suggested as an attractive and selective point for 
intervention in estrogen-dependent proliferative disorders including gynecological cancers 
by inhibiting the excessive formation of potent 17β-estradiol. Our currently investigated 
nonsteroidal 17β-HSD1 inhibitor compounds chemically related to natural polyphenols 
exhibited considerable anticancer activity. 
These results indicate that it is possible to combine direct antiproliferative activity with 
17β-HSD1 inhibition resulting in novel class of agents. Having in hand such compounds, it 
might be possible to further investigate whether these molecules with a dual mode of 
action are superior to pure 17β-HSD1 inhibitors and might lead to the discovery of superior 
drugs for the treatment of estrogen-dependent proliferative disorders. 
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Consequently, our presented results concerning the antiproliferative action of chemically 
different agents with diverse pharmacological spectrum may contribute to design of novel 
anticancer agents.  
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